MDK 202
Alternative Names: MDK-202Latest Information Update: 19 Nov 2020
At a glance
- Originator Medikine
- Class Antineoplastics; Immunoglobulin fragments; Peptides
- Mechanism of Action Interleukin 15 receptor modulators; Interleukin 2 receptor modulators; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 10 Nov 2020 Preclinical trials in Cancer in USA (Parenteral) prior to November 2020
- 10 Nov 2020 Pharmacodynamics data from preclinical studies presented at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020)
- 01 Jan 2013 Medikine receives SBIR grant from Department of Health and Human Services for MDK 202 development in Cancer